Latest news
15 September 2021
Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces extension of its fundraising round to a current aggregate total of US $125 million (£92 million GBP). The round was led by Bridford Investments Limited and Novator Partners. Demand for Touchlight’s proprietary synthetic DNA vector, dbDNA™, has grown rapidly … Continued
28 July 2021
Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats
Touchlight’s doggybone DNA™ to be used in Pandemic Prevention Platform (P3) programme funded by Defense Advanced Research Projects Agency (DARPA) • For the first time, novel synthetic DNA combined with state-of-the-art delivery will be used to deliver neutralising antibody therapies and enable faster pandemic response • Touchlight recently raised £42 million ($58 million) to expand … Continued
11 March 2021
Touchlight raises £42 million ($58 million) to meet unprecedented global DNA demand
Touchlight raises £42 million ($58 million) to meet unprecedented global DNA demand Completed facility will have capacity to manufacture up to 1 kg GMP DNA per month, enough for more than 1 billion Covid-19 vaccine doses Company’s growth driven by exceptional demand in all areas of genetic medicine, including mRNA and viral vectors for Covid-19 … Continued
3 December 2020
Touchlight appoints Satish Muchakayala as Director of Regulatory Affairs
Touchlight announces the appointment of Satish Muchakayala to the newly created position of Director of Regulatory Affairs. Hampton, UK – 03 December 2020 Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of Satish Muchakayala to the newly created position of Director of Regulatory Affairs. In … Continued
3 December 2020
John Dwyer joins Touchlights board of directors
Hampton, UK – 03 December 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today announces the appointment of John Dwyer to the Company’s Board of Directors as a Non-Executive Director. John spent over 20 years as partner at PwC UK, where he led the Global Deals Business and sat … Continued
17 November 2020
Touchlight wins prestigious Lloyds Bank National Business Award
Hampton, UK – 11 November 2020 – Touchlight was announced the winner of The LDC Growth Through Innovation Award at the prestigious 2020 Lloyds Bank National Business Awards, which took place during an online ceremony on 10 November. Commenting on the awards, Jonny Ohlson, Founder and Executive Chairman of Touchlight, said: “It is a privilege to … Continued
15 October 2020
Touchlight appoints Karen Fallen as CEO of Touchlight DNA Services
Former Lonza President of Biologics Manufacturing joins to continue rapid expansion of DNA contract manufacturing Touchlight’s synthetic dbDNA in high demand as starting material in the manufacture of advanced therapies such as mRNA vaccines and cell and gene therapies Hampton, UK – 15 October 2020 Touchlight, a biotechnology company focused on the discovery and development … Continued
29 September 2020
Touchlight Genetics and Stonehaven Incubate form Touchlight Aquaculture
London, England / Andermatt, Switzerland – 29 September 2020 Touchlight Genetics LLC and Stonehaven Incubate AG have formed a new joint venture company, Touchlight Aquaculture LLC, to combine expertise, intellectual property and platform technology. The new company will utilize Touchlight Genetics’ innovative DNA-based Doggybonetm platform to develop new vaccine solutions, focused on providing solutions exclusively … Continued
21 August 2020
Touchlight announces development of a vaccine against COVID-19
Hampton, London, UK – 21 August 2020 Touchlight is pleased to announce it has begun development of a vaccine against SARS-CoV-2 (COVID-19). Bringing together Touchlight’s technology with a team of vaccine development and infectious and respiratory disease experts, this program seeks to augment the existing vaccine development landscape, guided by emerging clinical data and the … Continued
29 July 2020
Cancer Research UK, University of Southampton and Touchlight Genetics Partner to develop head and neck cancer vaccine
Hampton, London, Southampton, UK – 29 July 2020 Cancer Research UK, the University of Southampton and Touchlight Genetics, a London based biotechnology company, today (Wednesday) announce a new clinical development partnership to progress a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC). HNSCC is the … Continued
18 June 2020
Touchlight to develop biobatteries with potential to address limitations of portable power supply
Hampton, UK – 18 June 2020 – Supported by the Office of Naval Research Global (ONR Global) and the Defense Science and Technology Laboratory (DSTL), Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, is working together with the Minteer Lab, University of Utah, to develop a DNA-enabled biobattery that could … Continued
5 June 2020
Touchlights’s chairman to help lead UK COVID-19 vaccine effort
Dr. Clive Dix appointed as Deputy Head of the UK’s Vaccine Taskforce Hampton, UK – 5 June 2020 – Touchlight, a biotechnology company focused on the discovery and development of DNA-based genetic medicines, today commented on the news that its Chairman, Dr. Clive Dix, has been appointed Deputy Chair of the UK’s Vaccine Taskforce. In this … Continued